image credit: Unsplash

AstraZeneca preps COVID-19 vaccine for FDA filing armed with 79% efficacy stat

March 22, 2021


With the U.S. vaccinating millions of people per day and racing against new COVID-19 variants, a fourth shot looks to be on its way.

In a phase 3 trial in the U.S., Peru and Chile, AstraZeneca’s vaccine—which is authorized in Europe and many other countries but not yet in the U.S.—posted 79% overall efficacy against symptomatic COVID-19. The shot also showed 100% protection against severe disease, hospitalization and death. In participants over 65, its efficacy rang in at 80%, even better than the overall figure.

Read More on FiercePharma